Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03055247 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Combination of Ibuprofen, G-CSF and Plerixafor as Stem Cells Mobilization Regimen in Patients Affected by X-CGD

Study acronym: XCGD-MOBI
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Completion date: Jul 18, 2023 to Jul 18, 2026v4
  2. Primary completion date: Sep 2017 to Jul 13, 2023 Completion date: Aug 2018 to Jul 18, 2023 · Start date: Nov 2015 to Nov 6, 2015 · Publications: details revised at 26 of 26 entriesv3 Show 3 more changesShow less
    • Completion date: Aug 2018 to Jul 18, 2023
    • Start date: Nov 2015 to Nov 6, 2015
    • Publications: details revised at 26 of 26 entries
  3. Lead sponsor: Ciceri Fabio to IRCCS San Raffaelev2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase II exploratory study conducted to evaluate the safety and efficacy of the combination of Ibuprofen, G-CSF and Plerixafor as stem cell mobilization regimen in patients affected by X-CGD.
Trial Details
NCT Number NCT03055247
Lead Sponsor IRCCS San Raffaele
Collaborators: Fondazione Telethon
Conditions Chronic Granulomatous Disease X-linked (X-CGD)
Enrollment 3 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov